Kwong Wah Hospital is a 1,141-bed public district general hospital in Yau Ma Tei, Hong Kong. Located on 25 Waterloo Road, the hospital was founded by the Tung Wah Group in 1911, and managed by the Hospital Authority since 1991. It provides a full range of medical services to the population of West Kowloon and Wong Tai Sin. It is Kowloon West Cluster's major acute teaching hospital, and also a Neurosurgical and Antenatal Diagnosis referral centre. The Hospital has established various clinical centers, including Lai Kwok Wing Urology Centre, Minimally Invasive Surgery Training Centre and Chan Feng Men Ling Cardiac Centre. There are integrated Breast Centre and Dr Stephen Chow Chun-kay Assisted Reproduction Centre. It has established a Community Based Geriatric Service, Respiratory Care Unit, Acute Stroke Unit, TWGHs BOCHK Diabetes Centre, Wong Wha San Renal Memorial Centre, and a Nuclear Medicine site. Kwong Wah Hospital is also a pioneer in Integrative Chinese and Western Medicine. TWGHs (Tung Wah Group of Hospitals) has established TWGHs Wilson T S Wang Integrated Chinese and Western Medicine Treatment Centre in Kwong Wah. The hospital has participated through joint consultation for designated diseases under protocols which developed by both Chinese Medicine and Western Medicine practitioners.The former Main Hall Building of Kwong Wah Hospital is preserved and houses the Tung Wah Group of Hospitals Museum..
Randomized controlled trials (RCTs) are essential for evaluating surgical interventions, yet adherence to CONSORT reporting guidelines remains inconsistent. Transparent reporting is especially critical in rhinoplasty due to individualized outcomes and diverse surgical techniques. This systematic review assesses adherence to the CONSORT-NPT guidelines in rhinoplasty RCTs and identifies key reporting deficiencies. A systematic review following PRISMA and AMSTAR-2 guidelines was conducted. Databases including PubMed, Embase, Cochrane Library, Google Scholar, and MEDLINE were searched for rhinoplasty RCTs published between 2017 and 2024. Adherence to the 25-item CONSORT-NPT checklist was evaluated, and study quality was assessed using the Cochrane Risk of Bias tool and GRADE framework. Descriptive statistics summarized compliance trends, and correlations with journal impact factor and author count were analyzed. Ninety-seven studies met inclusion criteria, with a mean CONSORT adherence of 68.8 www.springer.com/00266 .
BACKGROUND:This study evaluates the performance of a general-purpose (GPT-4) and a medically fine-tuned (Med-LM) large language model (LLM) in classifying liver lesions from unstructured Computed Tomography (CT) reports. METHODS:Consecutive CT reports (2014-2020) from five institutions were input into GPT-4 and Med-LM withsimple (sp)andoptimised (op) prompts. Lesion-andpatient-level performance were benchmarked against LI-RADS scores assigned by two radiologists, and report quality was analysed using a5-point Likert scale. RESULTS:A total of 296 CT reports (mean age, 64.6 years ± 11.3 [SD]; 193 men; 654 lesions) were included. Lesion- and patient-level accuracies for LI-RADS scoring ranged from 40.8% (Med-LMsp) to 61.3% (Med-LMop) and from 27.7% (Med-LMsp) to 52.4% (Med-LMop), respectively. When dichotomized into malignant and benign lesions, lesion- and patient-level accuracies rose to 56.1% (GPT-4sp) - 82.3% (Med-LMop) and 71.3% (Med-LMsp) - 86.5% (Med-LMop). Med-LMop demonstrated the highest performance in all analyses and was statistically superior to other models (all p < 0.001). Non-classification rates ranged between 12.7% (Med-LMop) and 40.5% (GPT-4sp), particularly for benign lesions. Kappa values were weak to moderate between the two reviewers in different aspects of report quality (0.471-0.766), and Likert scores for lesion information differed significantly between correctly and incorrectly classified lesions (all p ≤ 0.04). Repeatability varied widely from 12.7% (Med-LMop) to 39.0% (GPT-4sp). CONCLUSIONS:Med-LM outperforms GPT-4 in classifying liver lesions from unstructured CT reports with both models better at detecting malignancy than full LI-RADS classification. However, high misclassification rates and inconsistent repeatability hinder their clinical use.
Introduction:A novel dopamine-receptor small molecule inhibitor, ONC201, was observed to elicit a treatment response in patients with H3K27M-altered diffuse midline gliomas (DMG). Given restricted access to this therapy, an alternative formulation from Germany (GsONC201) was made available by compassionate means. We describe the treatment outcomes of these patients and our experience with GsONC201. Methods:This was a multicenter retrospective study of adult Chinese patients with histologically confirmed H3K727M-altered DMG. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival, the observed response rate (ORR) at 3 months after radiotherapy and GsONC201-associated adverse effects. Results:Twenty-seven patients, median age of 40 years (range: 31-52), were identified. Fifty-two percent (14/27) of tumors arose from the thalamus followed by the pons (22%, 6). Eighty-five percent (23/27) of patients received standard-of-care (SOC) fractionated radiotherapy. Thirty-seven percent (10/27) of patients received GsONC201 of which 80% (8/10) started it as first-line monotherapy after SOC. The mOS of the entire cohort was 17.4 months (IQR: 12.1-30.0). GsONC201 + SOC patients (8) had a mOS of 18.9 months (IQR: 11.3-54.4) compared to 16.0 months (IQR: 12.5-27.6) for SOC-alone patients (13, P value: .57). The ORR was 33% (7/21) and 63% of GsONC201 + SOC patients had a treatment response compared to 15% of SOC-alone patients (P value: .01). No GsONC201-associated adverse effects were observed. Conclusion:This is the first real-world study to review the outcomes of first-line imipridone-class agent therapy in adult Chinese DMG patients. GsONC201 was well-tolerated, but its effect on OS remains unknown.
Alternating electric fields (AEF) therapy has been shown to improve the overall survival of patients with WHO grade 4 astrocytoma. Few have explored its impact on health-related quality-of-life (HRQoL) and caregiver stress. This was a prospective, multi-centre, registry-based study of adult patients with WHO grade 4 astrocytoma who received either AEF plus temozolomide chemoradiotherapy (AEF + CRT) or CRT alone, with EORTC QLQ-C30/BN20, CSI, and HK-MoCA assessments at baseline and every three months. The primary outcome was the global QLQ-30 score at 3 months after CRT. Secondary outcomes included the QLQ-30 functional score, symptom scores and the caregiver stress index (CSI) at 3 months. 88 patients, 48 AEF + CRT and 40 CRT-alone, were reviewed. The mean AEF duration was 10 ± 8 months. At 3 months, AEF + CRT patients had significantly lower global QLQ-C30 scores than CRT-alone patients (44 ± 22 vs. 66 ± 20; between-group difference 22 points; p < 0.001), exceeding the established minimally important difference of 4–6 points for glioma. On multivariable analysis, AEF therapy (adjusted OR 0.09, 95
